Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

Biotech

News

Health Care

General

TG Therapeutics Announced Updated Data Presentations Including New Five-year Data From ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) For Relapsing Forms Of Multiple Sclerosis At The 2024 European Committee For Treatment And Research In Multiple Sclerosis Annual Meeting - TG Therapeutics (NASDAQ:TGTX)

Benzinga Newsdesk

TG Therapeutics

TGTX

TG Therapeutics Announced Updated Data Presentations Including New Five-year Data From ULTIMATE I & II Phase 3 Trials Evaluating Briumvi (Ublituximab-xiiy) For Relapsing Forms Of Multiple Sclerosis At The 2024 European Committee For Treatment And Research In Multiple Sclerosis Annual Meeting

Comments